fda tirzepatide ban F.D.A. Approves New Obesity Drug That Will Compete With Wegovy The Impact of New FDA

Tirzepatide mimics the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)

Some PCPs aren't experienced with anti-obesity medication prescribing

By promoting earlier satiety and fewer cravings, tirzepatide makes it easier to maintain a calorie-controlled diet and achieve sustainable weight loss

When using Tirzepatide for weight loss, its crucial to maintain ongoing monitoring and make necessary adjustments to the dosage under a physicians guidance

Healthy habits help you see progress sooner and maintain it longer

Patients who used phentermine continuously for more than 12 months maintained a 7.4% weight loss at the 24-month mark